Monthly Archives April 2017

The following products will be reference priced from 1 May 2017, which comes about from an alternative being award the Sole Supply within the next few months. We are highlighting these so that you have time to manage the transition. With price support from the suppliers ProPharma / PWR will be reducing the pricing to match the new subsidy from…

Patients on Efexor XR do not need to change brands until 31 August 2017 and then they may well choose to stay on it as private market with a nominal cost. The important part for now is they can continue on the current medication. Also effective 1 June 2017 the Special Authority for Efexor XR will be removed. Could not…

As you are all aware there are ongoing issues with supply for the following products: Ensure Powder Chocolate 850 gm Pharmacode 2504324 Ensure Powder Vanilla 850 gm Pharmacode 2504316 Pediasure Powder Vanilla 850 gm Pharmacode 2457652 Fortisip Powder Vanilla 350 gm Pharmacode 2461005 All products are being allocated to us by the supplier and we have accordingly set allocations for…

Confirming the major change coming up that we all need to be aware of and manage our stocks accordingly. Effective from 1 June 2017 Celecoxib Pfizer Capsules 100 mg and 200mg will be listed and fully funded in the Pharmaceutical Schedule, replacing Celebrex in the New Zealand market. The current ex-manufacturer price of: - Celebrex Caps 100 mg 60 is…

As advised via Pharmac Tender announcement 31 March 2017 there is to be a change in the listing and future HML Status. New listing from 1 March 2018 - Piperacillin with Tazobactum Sandoz. The incumbent brand Hospira will be deleted from the HML effective from 1 May 2018. On that basis we would recommend you continue to purchase the incumbent…

As advised via Pharmac Tender announcement 31 March 2017 there is to be a change in the listing and future sole supply. New listing from 1 July 2017 - Clonidine Patches Mylan in all three strengths. The incumbent brand Catapress TTS will be reference priced to Clonidine Mylan from 1 September 2017. The subsidy will decrease between 42.19% and 45.59%.…

As advised via Pharmac Tender announcement 31 March 2017 there is to be a change in the listing and future sole supply. New listing from 1 October 2017 - Buscopan Tablets 100 pack. The incumbent brand Gastrosoothe Tablets will be reference priced to Buscopan Tablets from 1 December 2017. The subsidy will reduce by around 19.72%. At this time we…

As advised via Pharmac Tender announcement 31 March 2017 there is to be a change in the listing and future sole supply. New listing from 1 October 2017 - Escitalopram-Apo ┬áin both 10 mg and 20 mg. The incumbent brand Escitalopram Airflow will be reference priced to Escitalopram-Apo from 1 December 2017. The subsidy will reduce between 20.71% and 20.83%.…

12
Close